ES2721930T3 - Composición inmunogénica - Google Patents

Composición inmunogénica Download PDF

Info

Publication number
ES2721930T3
ES2721930T3 ES13801540T ES13801540T ES2721930T3 ES 2721930 T3 ES2721930 T3 ES 2721930T3 ES 13801540 T ES13801540 T ES 13801540T ES 13801540 T ES13801540 T ES 13801540T ES 2721930 T3 ES2721930 T3 ES 2721930T3
Authority
ES
Spain
Prior art keywords
fragment
immunogenic composition
toxin
isolated
clostridium difficile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13801540T
Other languages
English (en)
Inventor
Dominique Boutriau
Sophie Marie Jeanne Valentine Germain
Hugues Wallemacq
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of ES2721930T3 publication Critical patent/ES2721930T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición inmunogénica que comprende: a) un polipéptido que comprende un fragmento aislado de toxina A de Clostridium difficile y un fragmento aislado de toxina B de Clostridium difficile; y b) un coadyuvante que comprende una fracción de saponina inmunológicamente activa presentada en forma de un liposoma; en la que el polipéptido comprende un fragmento del dominio de repetición de la toxina A y un fragmento del dominio de repetición de la toxina B.
ES13801540T 2012-12-05 2013-12-03 Composición inmunogénica Active ES2721930T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201221875 2012-12-05
PCT/EP2013/075405 WO2014086787A1 (en) 2012-12-05 2013-12-03 Immunogenic composition

Publications (1)

Publication Number Publication Date
ES2721930T3 true ES2721930T3 (es) 2019-08-06

Family

ID=49724573

Family Applications (2)

Application Number Title Priority Date Filing Date
ES19159001T Active ES2939307T3 (es) 2012-12-05 2013-12-03 Composición inmunogénica
ES13801540T Active ES2721930T3 (es) 2012-12-05 2013-12-03 Composición inmunogénica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES19159001T Active ES2939307T3 (es) 2012-12-05 2013-12-03 Composición inmunogénica

Country Status (22)

Country Link
US (2) US9694064B2 (es)
EP (2) EP3513806B1 (es)
JP (2) JP6290918B2 (es)
CN (2) CN112807422A (es)
AR (1) AR093712A1 (es)
AU (1) AU2013354186A1 (es)
BR (1) BR112015012841B1 (es)
CA (1) CA2893435C (es)
CY (1) CY1121560T1 (es)
DK (2) DK2928489T3 (es)
ES (2) ES2939307T3 (es)
FI (1) FI3513806T3 (es)
HR (2) HRP20230359T1 (es)
HU (2) HUE061273T2 (es)
LT (2) LT2928489T (es)
PL (2) PL3513806T3 (es)
PT (2) PT2928489T (es)
SG (1) SG11201503861UA (es)
SI (2) SI3513806T1 (es)
TR (1) TR201905272T4 (es)
WO (1) WO2014086787A1 (es)
ZA (1) ZA201503927B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2351578T (lt) * 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
ES2969952T3 (es) 2011-04-22 2024-05-23 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
HRP20230359T1 (hr) * 2012-12-05 2023-06-09 Glaxosmithkline Biologicals Sa Imunogeni pripravak
JP6688233B2 (ja) * 2014-06-25 2020-04-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム クロストリジウム・ディフィシル免疫原性組成物
ES2672045T3 (es) * 2014-07-25 2018-06-12 Biosynth S.R.L. Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas
US10533036B2 (en) 2015-02-19 2020-01-14 Immune Biosolutions Inc Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3433264A4 (en) 2016-03-21 2019-08-28 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR INHIBITING WNT SIGNALING
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG11201908376UA (en) * 2017-03-15 2019-10-30 Novavax Inc Methods and compositions for inducing immune responses against clostridium difficile
CN107397956A (zh) * 2017-08-08 2017-11-28 南开大学 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用
CN112512556A (zh) 2018-01-16 2021-03-16 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
EP3972638A4 (en) * 2019-05-21 2023-09-13 The Regents Of The University Of California VACCINE COMPOSITION FOR CLOSTRIDIUM DIFFICILE
WO2021255690A2 (en) * 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
TW202438104A (zh) * 2022-12-13 2024-10-01 美商輝瑞股份有限公司 誘發針對困難梭狀芽孢桿菌之免疫反應的免疫原性組成物和方法
CN120615016A (zh) 2023-02-02 2025-09-09 葛兰素史克生物有限公司 免疫原性组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
WO1988009797A1 (en) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69015222T2 (de) 1989-02-04 1995-05-04 Akzo Nv Tocole als Impfstoffadjuvans.
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CN1176658A (zh) 1994-10-24 1998-03-18 蛇药制品有限公司 治疗和预防艰难梭菌疾病的疫苗和抗毒素
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP1024826B1 (en) 1997-10-20 2005-03-16 Acambis, Inc. Passive immunization against clostridium difficile disease
EP2502998A3 (en) 1999-04-09 2013-02-27 Intercell USA, Inc. Recombinant toxin A/ToxinB vaccine against clostridium difficile
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
US20020065396A1 (en) 2000-03-28 2002-05-30 Fei Yang Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0525321D0 (en) * 2005-12-13 2006-01-18 Glaxosmithkline Biolog Sa Novel compositions
ES2397714T3 (es) * 2006-10-12 2013-03-08 Glaxosmithkline Biologicals S.A. Vacuna que comprende un adyuvante de emulsión de aceite en agua
GB0711858D0 (en) 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
EP2198007B1 (en) 2007-09-14 2017-10-25 Sanofi Pasteur Biologics, LLC Pharmaceutical compositions containing clostridium difficile toxoids a and b
US20120164178A1 (en) * 2008-04-16 2012-06-28 Ballou Jr William Ripley Vaccine
EP2318515A4 (en) * 2008-08-06 2012-11-14 Emergent Product Dev Uk Ltd DIFFICULT CLOSTRIDIUM VACCINES, AND METHODS OF USE
SMT201700124T1 (it) * 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
EP3327126A1 (en) * 2011-05-27 2018-05-30 GlaxoSmithKline Biologicals S.A. Immunogenic composition
HRP20230359T1 (hr) * 2012-12-05 2023-06-09 Glaxosmithkline Biologicals Sa Imunogeni pripravak

Also Published As

Publication number Publication date
US20170340719A1 (en) 2017-11-30
PT3513806T (pt) 2023-03-02
LT2928489T (lt) 2019-04-10
SI3513806T1 (sl) 2023-04-28
ZA201503927B (en) 2017-11-29
HUE043091T2 (hu) 2019-08-28
US20150313984A1 (en) 2015-11-05
PL2928489T3 (pl) 2019-07-31
ES2939307T3 (es) 2023-04-20
CN104884081A (zh) 2015-09-02
EP2928489A1 (en) 2015-10-14
HUE061273T2 (hu) 2023-06-28
WO2014086787A1 (en) 2014-06-12
DK3513806T3 (da) 2023-02-27
JP2018104446A (ja) 2018-07-05
SI2928489T1 (sl) 2019-05-31
HRP20190711T1 (hr) 2019-05-31
EP3513806B1 (en) 2023-01-25
CY1121560T1 (el) 2020-05-29
SG11201503861UA (en) 2015-06-29
PL3513806T3 (pl) 2023-05-15
JP6290918B2 (ja) 2018-03-07
CA2893435C (en) 2024-11-12
CA2893435A1 (en) 2014-06-12
DK3513806T5 (da) 2024-09-02
FI3513806T3 (fi) 2023-04-26
EP3513806A1 (en) 2019-07-24
AU2013354186A1 (en) 2014-06-12
CN112807422A (zh) 2021-05-18
US10130694B2 (en) 2018-11-20
PT2928489T (pt) 2019-05-28
BR112015012841B1 (pt) 2022-05-03
HRP20230359T1 (hr) 2023-06-09
BR112015012841A2 (pt) 2017-09-26
LT3513806T (lt) 2023-04-11
JP6626521B2 (ja) 2019-12-25
EP2928489B1 (en) 2019-02-27
DK2928489T3 (en) 2019-04-23
TR201905272T4 (tr) 2019-05-21
JP2016502551A (ja) 2016-01-28
US9694064B2 (en) 2017-07-04
AR093712A1 (es) 2015-06-17

Similar Documents

Publication Publication Date Title
AR093712A1 (es) Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento
MX2015015239A (es) Composiciones y metodos.
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
BR112013000599A2 (pt) deuterado n-etil-n-fenil-1,2-di-hidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolino-3-carboxamida, os seus sais e suas utilizações
SI2909307T1 (sl) Kompozicije in metode, povezane z mutantnim toksinom clostridium difficile
BR112013000607A2 (pt) 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações
AR101455A1 (es) Molécula portadora
MX2015006915A (es) Preparacion de una bebida estable.
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
MX2016008903A (es) Composicion adhesiva fusionada por calor en espuma para unir empaques de envases.
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
UY35545A (es) Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación
BR112015020079A8 (pt) Composições para cuidado oral
MX392514B (es) Vacuna para estreptococo del grupo a.
TWD162230S (zh) 啤酒分配器
TWD162231S (zh) 啤酒分配器
UY4238Q (es) Silla con respaldo en forma trapezoidal
CO7051011A2 (es) Anticuerpos recombinantes con especificidad dual por gangliósidos y su uso
CL2011002741S1 (es) Reposera.
AR088908A1 (es) Vacuna
TWD186746S (zh) 破碎機
EA201390670A1 (ru) Новый адъювант
GB201106162D0 (en) Combination vaccine